In 2023, with the outstanding advantage of the advanced machine learning system and large genetic data, Gene Solution has invented a SPOT-MAS™ liquid biopsy technology to enhance the early-stage detection of many cancers as the next breakthrough pillar.
SPOT-MAS™ accurately detects abnormal genomic factors of multiple common types of cancer including liver cancer, lung cancer, breast cancer and colorectal cancer, stomach cancer.
With a higher performance rate of detecting rare circulating tumor DNA (ctDNA) and lower costs compared to market standards, SPOT-MAS™ initiates affordable liquid-biopsy Point-Of-Care (POC) for cancer management in developing countries where 75% of global cancer deaths, proved by researchers.
Also in 2023, Gene Solutions launched K-TRACK™ — a ctDNA-based tool to monitor cancer recurrence. It detects Minimal Residual Disease and provides critical insights for a patient’s comprehensive genomic profile, allowing precise identification of treatment eligibility — predicting disease-free survival and early relapse detection in cancer patients.
Once a personalized genetic profile is established, Gene Solutions tracks ctDNA-MRD based on each patient’s profile. K-TRACK™ has been validated in scientific journals for high sensitivity and specificity. It can predict recurrence up to 19 months earlier than traditional imaging methods.